ValiRx Plc (LON:VAL)‘s stock had its “speculative buy” rating reaffirmed by analysts at Beaufort Securities in a research note issued on Friday. They presently have a GBX 6.50 ($0.08) price objective on the stock. Beaufort Securities’ price target would suggest a potential upside of 266.20% from the stock’s current price.

ValiRx Plc (LON:VAL) traded down 1.389% during midday trading on Friday, reaching GBX 1.775. The company had a trading volume of 224,875 shares. The company’s market cap is GBX 2.32 million. ValiRx Plc has a 52-week low of GBX 1.65 and a 52-week high of GBX 11.49. The company’s 50-day moving average is GBX 1.91 and its 200 day moving average is GBX 2.28.

TRADEMARK VIOLATION NOTICE: This article was first published by American Banking News and is the property of of American Banking News. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at

About ValiRx Plc

ValiRx plc is a biopharmaceutical company. The principal activity of the Company is the development of oncology therapeutics and companion diagnostics. It focuses on the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. It operates in two business segments: drug development and the sale of self-test drug kits.

Receive News & Ratings for ValiRx Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ValiRx Plc and related companies with's FREE daily email newsletter.